Hypera S.A. (OTCMKTS:HYPMY – Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 4,900 shares, an increase of 63.3% from the July 15th total of 3,000 shares. Based on an average daily volume of 5,300 shares, the short-interest ratio is presently 0.9 days.
Hypera Trading Down 0.4 %
OTCMKTS HYPMY traded down $0.02 during mid-day trading on Friday, reaching $5.63. 700 shares of the company’s stock traded hands, compared to its average volume of 22,777. Hypera has a 1-year low of $4.82 and a 1-year high of $8.38. The company has a fifty day simple moving average of $5.24 and a 200-day simple moving average of $5.88. The company has a market cap of $3.56 billion, a price-to-earnings ratio of 9.65 and a beta of 1.03.
Hypera (OTCMKTS:HYPMY – Get Free Report) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.15 earnings per share for the quarter. The company had revenue of $420.00 million for the quarter.
Hypera Company Profile
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Featured Stories
- Five stocks we like better than Hypera
- 3 Best Fintech Stocks for a Portfolio Boost
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- What is a Stock Market Index and How Do You Use Them?
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.